Oncotarget

Research Papers:

Metformin treatment reduces temozolomide resistance of glioblastoma cells

Seung Ho Yang, Shenglan Li, Guangrong Lu, Haipeng Xue, Dong H. Kim, Jay-Jiguang Zhu and Ying Liu _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:78787-78803. https://doi.org/10.18632/oncotarget.12859

Metrics: PDF 1382 views  |   HTML 1800 views  |   ?  


Abstract

Seung Ho Yang1,2,3,*, Shenglan Li1,3,*, Guangrong Lu1, Haipeng Xue1,3, Dong H. Kim1,3, Jay-Jiguang Zhu1,**, Ying Liu1,3,**

1Department of Neurosurgery, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA

2Department of Neurosurgery, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Suwon, South Korea

3Center for Stem Cell and Regenerative Medicine, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA

*These authors contributed equally to this work

**These authors contributed equally to this work

Correspondence to:

Jay-Jiguang Zhu, email: jay.jiguang.zhu@uth.tmc.edu

Ying Liu, email: ying.liu@uth.tmc.edu

Keywords: glioblastoma, metformin, temozolomide resistance, SOX2, global gene expression

Received: September 07, 2016     Accepted: October 14, 2016     Published: October 24, 2016

ABSTRACT

It has been reported that metformin acts synergistically with temozolomide (TMZ) to inhibit proliferation of glioma cells including glioblastoma multiforme (GBM). However, the molecular mechanism underlying how metformin exerts its anti-cancer effects remains elusive. We used a combined experimental and bioinformatics approach to identify genes and complex regulatory/signal transduction networks that are involved in restoring TMZ sensitivity of GBM cells after metformin treatment. First, we established TMZ resistant GBM cell lines and found that the resistant cells regained TMZ sensitivity after metformin treatment. We further identified that metformin down-regulates SOX2 expression in TMZ-resistant glioma cells, reduces neurosphere formation capacity of glioblastoma cells, and inhibits GBM xenograft growth in vivo. Finally, the global gene expression profiling data reveals that multiple pathways are involved in metformin treatment related gene expression changes, including fatty acid metabolism and RNA binding and splicing pathways. Our work provided insight of the mechanisms on potential synergistic effects of TMZ and metformin in the treatment of glioblastoma, which will in turn yield potentially translational value for clinical applications.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12859